Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05465408 · ClinicalTrials.gov registry record · NA

Culturally Aware AET Non-Initiation Intervention

A NA study of Breast Cancer and Survivorship, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
35
Enrollment target
11
Study locations

NCT05465408: Completed NA study of Breast Cancer and Survivorship, sponsored by Massachusetts General Hospital.

NCT05465408 is a NA study of Breast Cancer and Survivorship that has completed, run by Massachusetts General Hospital. The registered enrollment target is 35 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 11 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05465408, a NA study of Breast Cancer and Survivorship, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
35 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to examine the feasibility and acceptability of a brief, nurse-led intervention to support breast cancer survivors who have delayed initiation of hormonal therapy or who have concerns about starting hormonal therapy.

Primary Outcome

Feasibility will be demonstrated by enrollment (\>50% of eligible and approached patients will enroll), retention (\>70% of enrolled participants will complete the two intervention sessions) and attendance (≥70% of participants completing at least one session).

Interventions

  • BEHAVIORAL Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention

Study Locations (11)

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston
  • Dana-Farber Cancer Institute - Boston
  • Dana-Farber Cancer Institute at St Elizabeth's Medical Center - Brighton
  • Emerson Hospital/MGH Cancer Center - Concord
  • Mass General at North Shore Cancer Center - Danvers
  • Dana-Farber Brigham Cancer Center - Foxborough - Foxborough
  • Dana-Farber Cancer Institute - Merrimack Valley - Methuen
  • Dana-Farber Brigham Cancer Center at Milford Regional Medical Center - Milford
  • Mass General at Newton Wellesley Hospital - Newton
  • Dana-Farber Brigham Cancer Center with South Shore Hospital - Weymouth

New Hampshire

  • Dana-Farber/New Hampshire Onoclogy-Hematology - Londonderry

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2022-07-21
Est. Completion 2024-11-20
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT05465408 record still lists

NCT05465408 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention is the first listed.

NCT05465408 lists 11 locations in 2 states (Massachusetts, New Hampshire).

Frequently Asked Questions

What is clinical trial NCT05465408 about?

NCT05465408 is a clinical study titled "Culturally Aware AET Non-Initiation Intervention". The purpose of this study is to examine the feasibility and acceptability of a brief, nurse-led intervention to support breast cancer survivors who have delayed initiation of hormonal therapy or who have concerns about starting hormonal therapy.

What is the current status of trial NCT05465408?

This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2022-07-21. Estimated completion is 2024-11-20.

What conditions does trial NCT05465408 study?

This clinical trial studies the following conditions: Breast Cancer, Survivorship, Treatment Adherence, Treatment Refusal, Treatment Compliance.

What interventions are being tested in trial NCT05465408?

The interventions under investigation include: Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT05465408?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05465408 being conducted?

This trial has 11 study locations across Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05465408's enrollment target sits among peer trials

35 922nd of 1224 higher than 298 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01697371 · 35 participants · NA

    Proton Therapy in the Treatment of Liver Metastases

  • NCT01940757 · 35 participants · Phase 1

    Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

  • NCT02235857 · 35 participants · NA

    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

  • NCT02637934 · 35 participants · Phase 1

    Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05465408, the US trial registry maintained by the National Library of Medicine. NCT05465408 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.